This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Industry experts believe that the luxury goods market is likely to remain healthy, courtesy of steady economic growth, higher consumer confidence and rising disposable income. Given this scenario, it will be wise to focus on some luxury goods’ stocks. Here we have highlighted one such stock Tiffany & Co. (TIF - Free Report) , which holds a significant position in the world jewelry market due to its distinctive brand appeal.
MOV GOOS FOSL LUXTY
Tiffany & Co. (TIF) is flexing muscle to counter competition in the jewelry industry. The company, which has a long-term expected earnings growth rate of 11.8%, is banking on several strategic initiatives to enhance customer base.
SCVL URBN FOSL LUXTY
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Tiffany & Co. (TIF - Free Report) is slated to report first-quarter fiscal 2018 results on May 23. In the trailing four quarters, this designer, manufacturer and retailer of jewelry and other items has outperformed the Zacks Consensus Estimate by an average of 4.5%. In the last reported quarter, the company delivered a positive earnings surprise of 2.5%. Investors are counting on another estimate beat by Tiffany in the to-be-reported quarter.
In early 2002, just a few months after he officially took over as the new owner and chief executive officer of Brooks Brothers, Claudio Del Vecchio confronted the reality that the classic American retailer had largely lost its way.
RL NYTAB LUXTY
As competition is intensifying in the retail space, Tiffany & Co. (TIF - Free Report) is leaving no stone unturned to drive revenues. The company, which has a long-term expected earnings growth rate of 11.2%, is banking on several strategic initiatives to enhance customer base. The company's strategic endeavors have helped the stock to gain 8.5% compared with the industry’s decline of 1.2% in the past six months.
JWN ABX KSS M ABX LUXTY
Trade talk and politics could hang over the market in the coming week, even with a blast of earnings news providing a bright spot.
WFCNP DB STT.PRC STT.PRE NTRSP STT.PRD DGX STT.PRG MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA WFC.PRT WFC.PRR UFPI WFC.PRQ WFC.PRP NTRS WFC.PRO WFC.PRN WFC.PRY MS WFC.PRX WFC.PRW WFC.PRV KSU WFC WFC.WS STT GEC GE STLD UMPQ SYF BHI MS.PRI MS.PRK URI KSU.PR GNE TRI LUXTY
New Look Vision's growth strategy will allow them to take advantage of their economies of scale, as well as secure its position within the increasingly consolidated industry of optical retail.
EYE SAFLF BOSSY FLMNY KATE SAFLY HUGPF FLMNF BCI LUXTY
4h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
6h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET